Clinical utility of thoracic endosonography (EBUS/EUS-b) in mediastinal staging of patients with non-small cell lung cancer: comparison with integrated PET/CT—a real-life prospective study in Greece

Chrysikos, Serafeim; Gkiozos, Ioannis; Dimakou, Katerina; Ζervas, Εleftherios; Karampitsakos, Theodoros; Anyfanti, Maria; Tzouvelekis, Argyrios; Samitas, Κonstantinos; Gaga, Mina; Koulouris, Νikolaos; Vasileiadis, Ioannis; Syrigos, Konstantinos

doi:10.21037/jtd-20-1735

Cited by 6 publications

(4 citation statements)

References 41 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the contrary, agreement rates were considerably decreased in cases of severe IPF 19 . However, EBUS-TBNA/B in centers of expertise seems to be a safe procedure and maybe even safer than bronchoalveolar lavage 36,37 . Thus, patients with acceptable performance status might experience benefit from timely diagnostic interventions.…”

Section: A B Cmentioning

confidence: 98%

Diagnostic and Therapeutic Challenges for Patients with Idiopathic Pulmonary Fibrosis and Lung Cancer

Karampitsakos¹,

Bouros²,

Τzouvelekis³

2021

BRN

Self Cite

View full text Add to dashboard Cite

Section: A B Cmentioning

confidence: 98%

Diagnostic and Therapeutic Challenges for Patients with Idiopathic Pulmonary Fibrosis and Lung Cancer

Karampitsakos¹,

Bouros²,

Τzouvelekis³

2021

BRN

Self Cite

View full text Add to dashboard Cite

“…These logistical limitations can be partially overcome with endoscopic ultrasound bronchoscopy (EUS-B), in which bronchoscopists can be trained to perform EUS using the same EBUS bronchoscope inserted into the oesophagus [41]. This combined systematic approach has also been shown to improve sensitivity for detecting mediastinal nodal involvement [32,42 ▪ ,43]. In the multicentre, prospective SCORE study, the addition of EUS improved sensitivity by 9% compared to a targeted sampling strategy with EBUS alone [32].…”

Section: Complete Lung Cancer Staging – When Is It Indicated and What...mentioning

confidence: 99%

What is new in mediastinal staging?

Schwalk,

Niroula,

Schimmel

2023

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of review Appropriate staging is of utmost importance in nonsmall cell lung cancer (NSCLC), as the pathologic stage dictates both overall prognosis and appropriate therapeutic pathways. This article seeks to review the current recommendations for mediastinal staging of NSCLC and available modalities to achieve this. Landmark publications pertaining to recent advancements in NSCLC treatments are also highlighted and the role of specific bronchoscopic modalities for tissue acquisition are reviewed. Recent findings Recent advancements in the treatment of NSCLC have made accurate mediastinal staging more important than ever. Guidelines and recommendations outlining patients that warrant invasive mediastinal staging are available and a systematic approach should be utilized when sampling is performed. Ensuring the adequacy of tissue for the growing number of molecular biomarkers that must be tested has been the focus of many recent studies. Summary Appropriate mediastinal staging is crucial for the management of patients with NSCLC as is obtaining adequate tissue for diagnostic and therapeutic purposes. EBUS-TBNA is sufficient for the diagnosis of nonsmall cell and small cell lung carcinomas, but EBUS-guided intranodal forceps and cryobiopsy may provide more optimal specimen for patients with benign disease, such as sarcoidosis, or in cases of lymphoma. Further studies are necessary to better delineate the role of these techniques in the diagnosis and staging of mediastinal diseases before they become the primary diagnostic modalities.

show abstract

“…Contrary to patients with mild-to-moderate IPF, level of agreement was lower for patients with severe IPF [17]. However, complications of EBUS-TBNB in specialized centers are rare and EBUS-TBNB might be safer compared with bronchoalveolar lavage [55,56]. Thus, patients with IPF and good performance status (ECOG: 1-2) could benefit from timely diagnosis and interventions.…”

Section: How Often Should We Screen Patients With Idiopathic Pulmonar...mentioning

confidence: 99%

Management of patients with idiopathic pulmonary fibrosis and lung cancer: challenges in clinical practice

Karampitsakos

Sampsonas

Herazo-Maya

et al. 2023

Current Opinion in Pulmonary Medicine

Self Cite

View full text Add to dashboard Cite

Purpose of review Idiopathic pulmonary fibrosis (IPF) is the nonmalignant, chronic lung disease with the worst prognosis. Prevalent comorbidities including lung cancer exert a negative impact on patients’ survival. However, there is considerable lack of knowledge on the diagnostic and therapeutic management of patients diagnosed with both clinical entities. This review article presents the main challenges in the management of patients with IPF and lung cancer and highlights future perspectives. Recent findings Recent registries for patients with IPF demonstrated that approximately 10% of patients developed lung cancer. Importantly, incidence of lung cancer was increasing remarkably over time in patients with IPF. Patients with IPF and otherwise technically operable lung cancer who underwent surgical resection had improved survival compared with those who did not undergo surgery. However, specific precautions perioperatively are crucial. Finally, the first randomized-controlled, phase 3 trial (J-SONIC trial) showed no significant difference in exacerbation-free survival for chemotherapy-naive patients with IPF and advanced nonsmall cell lung cancer that were allocated to receive carboplatin and nab-paclitaxel every 3 weeks with or without nintedanib. Summary Lung cancer is prevalent in IPF. Management of patients with IPF and lung cancer is challenging. A consensus statement aiming to attenuate confusion is greatly anticipated.

show abstract

Clinical utility of thoracic endosonography (EBUS/EUS-b) in mediastinal staging of patients with non-small cell lung cancer: comparison with integrated PET/CT—a real-life prospective study in Greece

Cited by 6 publications

References 41 publications

Diagnostic and Therapeutic Challenges for Patients with Idiopathic Pulmonary Fibrosis and Lung Cancer

Diagnostic and Therapeutic Challenges for Patients with Idiopathic Pulmonary Fibrosis and Lung Cancer

What is new in mediastinal staging?

Management of patients with idiopathic pulmonary fibrosis and lung cancer: challenges in clinical practice

Contact Info

Product

Resources

About